| 篇序 |
作者 |
論文題目 | 發表雜誌名稱 (含年月/卷期/頁次) |
屬性 (SCI、SSCI、IEEE) |
|---|---|---|---|---|
| 1 | 湯宏仁(1) | Nontyphoidal Salmonella urinary tract infection among elderly patients | J Microbiol Immunol Infect. 2016 Feb;49(1):157-8 | SCI |
| 2 | 湯宏仁(1) | Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity. | Front Microbiol. 2017 May 18;8:884 | SCI |
| 3 | 湯宏仁(C) | Coexistence of MCR-1 and NDM-9 in a clinical carbapenem-resistant Escherichia coli isolate | Int J Antimicrob Agents. 2017 Apr;49(4):517-518 | SCI |
| 4 | 湯宏仁(C) | Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA | Sci Rep. 2017 Jan 31;7:41758. | SCI |
| 5 | 湯宏仁(C) | Clostridium tetani bacteremia in a patient with cirrhosis following transarterial chemoembolization treatment for hepatocellular carcinoma. | J Microbiol Immunol Infect. 2018 Feb;51(1):155-156. | SCI |
| 6 | 湯宏仁(C) | The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms. | J Microbiol Immunol Infect. 2017 Oct 6. pii: S1684-1182(17)30226-8. | SCI |
| 7 | 湯宏仁(2) | Increasing resistance to fluoroquinolones among Haemophilus species in Southern Taiwan. | J Microbiol Immunol Infect. 2017 Apr;50(2):258-260 | SCI |
| 8 | 湯宏仁(3) | Desiccation and ethanol resistances of multidrug resistant Acinetobacter baumannii embedded in biofilm: The favorable antiseptic efficacy of combination chlorhexidine gluconate and ethanol. | J Microbiol Immunol Infect. 2017 Jun 28. pii: S1684-1182(17)30083-X. | SCI |
| 9 | 湯宏仁(4) | Impacts of Hypervirulence Determinants on Clinical Features and Outcomes of Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae | Microb Drug Resist. 2017 Apr;23(3):376-383 | SCI |
| 10 | 湯宏仁(4) | Timing of appropriate empirical antimicrobial administration and outcome of adults with community-onset bacteremia | Crit Care. 2017 May 26;21(1):119 | SCI |
| 11 | 湯宏仁(5) | Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia. | J Microbiol Immunol Infect. 2017 Jun 29. pii: S1684-1182(17)30098-1. | SCI |
| 12 | 湯宏仁(5) | Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance | J Microbiol Immunol Infect. 2017 Dec;50(6):931-939. | SCI |
| 13 | 湯宏仁(6) | Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia | Int J Antimicrob Agents. 2017 Sep;50(3):371-376 | SCI |
| 14 | 湯宏仁(6) | Klebsiella pneumoniae Isolates from Meningitis: Epidemiology, Virulence and Antibiotic Resistance. | Sci Rep. 2017 Jul 26;7(1):6634. | SCI |
| 15 | 湯宏仁(7) | Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014. | J Microbiol Immunol Infect. 2017 Aug 26. pii: S1684-1182(17)30188-3. | SCI |
| 16 | 湯宏仁(7) | Taiwan HIV Study Group. Evolution of hepatitis A virus seroprevalence among HIV-positive adults in Taiwan. | PLoS One. 2017 Oct 16;12(10):e0186338 | SCI |
| 17 | 湯宏仁(7) | Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-onset Bacteremia in Comparison with Third-generation Cephalosporin Therapy. | Antimicrob Agents Chemother. 2017 Jan 24;61(2) | SCI |
| 18 | 湯宏仁(8) | Taiwan HIV Study Group. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up | PLoS One. 2017 Jun 30;12(6):e0179870 | SCI |
| 19 | 湯宏仁(13) | Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan. | PLoS One. 2017 Feb 21;12(2):e0171596 | SCI |
